Biomerieux 69 Marcy L'etoile Stock Earnings Reports

bioMérieux delivered a strong 2025 with organic sales growth of 6.2%, reaching an annual revenue milestone of €4.0 billion. The company significantly outperformed the market (c. 1% market growth) and reported profitable operational leverage: contributive EBIT rose 16% organically to represent 17.9% of sales, and free cash flow improved ~40% to €462m. Commercial highlights include robust BIOFIRE performance (net installations up to ~28,500, +1,800 net installs in 2025), rapid SPOTFIRE expansion (installed base +110%, 6,400 instruments in 2025), strong instrument momentum in Microbiology (instruments +14%), and mid-teens growth in Pharma/Industrial Applications. China remained a headwind (notably Microbiology-driven; ~-40% market pressure in the region, company saw -14% in China in 2025), and immunoassays underperformed (-6% in 2025) though VIDAS KUBE instrument placements showed mid-teens instrument growth. Financially, gross margin improved (c. +90bp like-for-like) due to product mix and procurement/supply-chain efficiencies; reported net income was down due to one-off impairment/restructuring related to VITEK REVEAL/San Jose consolidation, but adjusted net income/EPS rose ~9%. The Board will propose a €0.98 per share dividend (+9%). The company remains net cash positive (~€108m) after acquisitions and investments. M&A: acquisitions include SpinChip (CE filing/clinical progress) and January acquisition of Accellix (€45m) to bolster pharma QC / cell & gene therapy offer. CapEx was elevated (~€328m; ~8% of sales) to support automation, capacity and instrument placements. GO.28 transformation is on track: sales CAGR target reconfirmed (7% average 2023–2028) and the company reaffirms at least 10% annual organic CEBIT growth; management upgraded its 2028 margin ambition to ~+500bp vs. 2023 (constant scope/Fx). CSR ambition was strengthened (scope 1–3 targets, net-zero by 2050, expanded access goals). 2026 guidance: group organic growth 5–7% (mid ~6%) and at least +10% organic EBIT; product-level guidance: non-respiratory ~+10%, SPOTFIRE +40–60%, Microbiology +3–5% (China still expected to decline mid-single digits), respiratory panels wide range (approx -3% to +3%) and immunoassays -5% to 0%. Management cautioned on FX headwinds (estimated -€50m to -€60m CEBIT impact at current rates) and on additional tariff pressure (~€20–24m impact expected in 2026). Key execution items to watch: SPOTFIRE rollout (including women’s health/vaginitis plans), SpinChip CE filing and clinical pathway for hs-cTnI (US clinical started), Accellix integration for Pharma QC, continued BIOFIRE installed-base growth, margin delivery from GO.28 efficiencies, and the magnitude/timing of respiratory season (flu) which largely drives the bottom end of 2026 guidance.